Trials / Recruiting
RecruitingNCT04121468
A Phase I Double Blind Study of Metformin Acting on Endogenous Neural Progenitor Cells in Children and Young Adults With Multiple Sclerosis
- Status
- Recruiting
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- Sponsor
- The Hospital for Sick Children · Academic / Other
- Sex
- All
- Age
- 10 Years – 25 Years
- Healthy volunteers
- Not accepted
Summary
A randomized multiple baseline feasibility trial where participants will start taking metformin at one of 3 randomly determined points (3-months, 6-months or 9 months) during the 12-month trial. All subjects will be on a daily dose of metformin for a minimum of 3 months and a maximum of 9 months.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Metformin | Each tablet contains 500mg of metformin hydrochloride |
| OTHER | Placebo | Each tablet contains no active drug ingredient |
Timeline
- Start date
- 2020-02-24
- Primary completion
- 2027-03-01
- Completion
- 2027-10-01
- First posted
- 2019-10-10
- Last updated
- 2025-09-23
Locations
1 site across 1 country: Canada
Source: ClinicalTrials.gov record NCT04121468. Inclusion in this directory is not an endorsement.